Natixis Advisors LLC Has $4.80 Million Stock Position in Repligen Corporation $RGEN

Natixis Advisors LLC lowered its holdings in Repligen Corporation (NASDAQ:RGEN) by 23.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,271 shares of the biotechnology company’s stock after selling 9,058 shares during the quarter. Natixis Advisors LLC owned 0.05% of Repligen worth $4,796,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. NewEdge Wealth LLC grew its holdings in Repligen by 5.3% in the 4th quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 75 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in Repligen by 0.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after buying an additional 100 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in Repligen by 5.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 101 shares during the last quarter. Northwestern Mutual Investment Management Company LLC grew its holdings in shares of Repligen by 1.0% during the 3rd quarter. Northwestern Mutual Investment Management Company LLC now owns 11,787 shares of the biotechnology company’s stock worth $1,576,000 after purchasing an additional 121 shares in the last quarter. Finally, Oppenheimer & Co. Inc. grew its holdings in shares of Repligen by 8.2% during the 4th quarter. Oppenheimer & Co. Inc. now owns 1,623 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 123 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

Shares of RGEN stock opened at $125.33 on Tuesday. The stock’s fifty day simple moving average is $118.88 and its 200 day simple moving average is $138.50. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The firm has a market cap of $7.07 billion, a price-to-earnings ratio of 139.26, a P/E/G ratio of 2.36 and a beta of 1.09. Repligen Corporation has a one year low of $100.99 and a one year high of $175.77.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. During the same quarter in the previous year, the company posted $0.39 EPS. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, analysts expect that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on RGEN shares. Barclays lifted their price objective on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Rothschild & Co Redburn set a $160.00 price objective on Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. HC Wainwright lifted their price objective on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Roth Mkm started coverage on Repligen in a report on Friday, April 17th. They set a “buy” rating and a $160.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.